Terms: = Ovarian cancer AND MALAT1, PRO1073, 378938, Q9UHZ2 AND Treatment
4 results:
1. Mechanistic actions of long non-coding RNA malat1 within the ovary and at the feto-maternal interface.
Adu-Gyamfi EA; Cheeran EA; Salamah J; Lee BK
Mol Biol Rep; 2024 Feb; 51(1):301. PubMed ID: 38353828
[TBL] [Abstract] [Full Text] [Related]
2. Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.
Eismann J; Heng YJ; Waldschmidt JM; Vlachos IS; Gray KP; Matulonis UA; Konstantinopoulos PA; Murphy CJ; Nabavi S; Wulf GM
J Cancer Res Clin Oncol; 2020 Feb; 146(2):503-514. PubMed ID: 31745703
[TBL] [Abstract] [Full Text] [Related]
3. Anticancer effects of Rosmarinic acid in OVCAR-3 ovarian cancer cells are mediated via induction of apoptosis, suppression of cell migration and modulation of lncRNA MALAT-1 expression.
Zhang Y; Hu M; Liu L; Cheng XL; Cai J; Zhou J; Wang T
J BUON; 2018; 23(3):763-768. PubMed ID: 30003749
[TBL] [Abstract] [Full Text] [Related]
4. Long non-coding RNA malat1 is up-regulated in ovarian cancer tissue and promotes SK-OV-3 cell proliferation and invasion.
Zou A; Liu R; Wu X
Neoplasma; 2016; 63(6):865-872. PubMed ID: 27565324
[TBL] [Abstract] [Full Text] [Related]
